Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131

After median follow-up of 20 months, RCT concluded that platinum based chemotherapy did not improve disease-free survival outcomes vs capecitabine (n=410; 3 year survival rates, 42% vs 49% respectively) and was associated with more grade 3/4 toxicities, therefore was terminated.

Journal of Clinical Oncology